Current Clinical Trials in Non-muscle Invasive Bladder Cancer

[1] Kamat AM(2016)Bladder cancer Lancet 388 2796-2810

[2] Hahn NM(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 466-477

[3] Efstathiou JA(2011)The EORTC tables overestimate the risk of recurrence and progression in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 423-430

[4] Lerner SP(2016)Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69 231-244

[5] Malmström P-U(2017)EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016 Eur Urol 71 447-461

[6] Choi W(2017)BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG Nat Rev Urol 14 244-255

[7] Guo CC(2013)Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin Urol Oncol Semin Orig Investig 31 1635-1642

[8] Lotan Y(2014)Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG European Urology 65 69-76

[9] Kassouf W(2016)High-risk non-muscle-invasive bladder cancer—therapy options during intravesical BCG shortage Curr Urol Rep 17 68-1238

[10] Sylvester RJ(1996)The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of Followup The Journal of Urology 155 1233-1123

[1] Kamat AM(2016)Bladder cancer Lancet 388 2796-2810

[2] Hahn NM(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 466-477

[3] Efstathiou JA(2011)The EORTC tables overestimate the risk of recurrence and progression in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 423-430

[4] Lerner SP(2016)Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69 231-244

[5] Malmström P-U(2017)EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016 Eur Urol 71 447-461

[6] Choi W(2017)BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG Nat Rev Urol 14 244-255

[7] Guo CC(2013)Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin Urol Oncol Semin Orig Investig 31 1635-1642

[8] Lotan Y(2014)Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG European Urology 65 69-76

[9] Kassouf W(2016)High-risk non-muscle-invasive bladder cancer—therapy options during intravesical BCG shortage Curr Urol Rep 17 68-1238

[10] Sylvester RJ(1996)The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of Followup The Journal of Urology 155 1233-1123